Cancer Cell Metabolism



NHI-2

NHI-2 is a selective inhibitor of Lactate Dehydrogenase A (LDHA) - IC₅₀ in vitro = 14.7 μ M (NADH), 10.5 μ M (Pyruvate)^{1,2}

Product No: 10-4555 10 mg 50 mg

CBR-5884

Potent and selective inhibitor of 3-phosphoglycerate dehydrogenase (PHGDH), IC $_{50}$ =33 μ M 3

Product No: 10-1588 5 mg 25 mg

AGI-5198

AGI-5198 is a potent (IC₅₀ = 70 nM) inhibitor of R132H mutant isocitrate dehydrogenase 1(IDH1).⁴

Product No. 10-4599 5 mg 25 mg

MF-438

MF-438 is a potent inhibitor of stearoyl-CoA desaturase 1 (SCD1) - IC_{50} = 2.3 nM.⁵

<u>Product No: 10-4558</u> 5 mg 25 mg

CT-2584

Cytotoxic agent that alters phospholipid biosynthesis via inhibition of CTP: choline-phosphate cytidylyltransferase.^{6,7}

Product No: 10-4560 5 mg 25 mg

R162

R162 is a selective inhibitor of Glutamate Dehydrogenase 1. Selective over 6-phosphogluconate and fumarate hydratase.⁸

Product No: 10-4603 10 mg 50 mg

Lonidamine

Lonidamine is a mitochondrial hexokinase inhibitor. The disruption of the mitochondrial transmembrane potential has also been linked to its apoptotic effects. 10

Product No: 10-4563 10 mg 50 mg

PFK15

PFK15 is a selective inhibitor of 6-Phosphofructo-2-kinase/fructose-2, 6-biphosphatase 3 (PFKFB3), an enzyme that is constitutively expressed in neoplastic cells and is required for the high glycolytic rate (Warburg effect) of these cells. 11,12,13

Product No: 10-4580 5 mg 25 mg

CB-839

CB-839 is a potent (IC₅₀ = 24 nM) inhibitor of glutaminase (KGA and GAC). 14,15


<u>Product No: 10-4556</u> 5 mg 25 mg

NG-497

NG-497 is the first small molecule inhibitor (IC $_{50}$ = 1 μ M) of human (and rhesus monkey) adipose triglyceride lipase (ATGL).

Product No: 10-4626 5 mg 25 mg

This is a small sample of our products in this research field. Visit our website or contact us for a complete listing or to discuss your specific needs.



NHI-2

CT-2584

CB-839

REFERENCES

- 1. Granchi et al. (2013) Org.Biomol.Chem. 11 6588
- 2. Maftouh et al. (2014) Br.J.Cancer 110 172
- 3. Mullarky et al. (2016) PNAS 113 1778
- 4. Popovici-Muller et al. (2012) ACS Med.Chem.Lett. 3 850
- 5. Leger et al. (2010) Bioorg. Med. Chem. Lett. 20 499
- 6. Finney et al. (2000) Cancer Res. 60 5204
- 7. Cheeseman et al. (2000) Br.J.Cancer 83 1599
- 8. Lingtao et al. (2015) Cancer Cell 27 257
- 9. Yasuda et al. (2001) J.Biol.Chem. 276 43994
- 10. Floridi et al. (1981) Cancer Res. 41 4661
- 11. Clem *et al.* (2013) Mol.Cancer Ther. **12** 1461 12. Zhu *et al.* (2016) PLoS One **11** e0163768
- 13. Li *et al.* (2017) J.Exp.Clin.Cancer Res. **36** 7
- 14. Gross *et al.* (2014) Mol.Cancer Ther. **13** 890
- 15. Jacque et al. (2015) Blood 126 134
- 16. Grabner et al. (2022) J. Am. Chem. Soc. 144 6237

400 Davis Dr. Suite 600 Plymouth Meeting, PA 19462 610-994-1134 sales@focusbiomolecules.com focusbiomolecules.com